Thomas Schiano, MD
Hepatology · New York, NYNPI 1689604191
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,311 of the $12,587 with a category attached, or 97.8%. 6 manufacturers reported payments, led by AstraZeneca at 29.1% of the total. Reporting peaked in 2021 at $6,901 and has fallen 99.8% since, to $17 in 2025. That places this record below the midpoint for hepatology clinicians in NY, where the typical reported total is $12,587.
Across 10 payments — averaging $1258.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Sanofi$4K
- Sanofi US Services Inc.$3K
- Mallinckrodt Hospital Products Inc.$2K
- Sumitomo Pharma America, Inc.$17
- Travere Therapeutics, Inc.$1
Across 12 payments — averaging $3960.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$24K
- La Jolla Pharmaceutical Company$23K
What the payments were for
- Consulting fees$12,31198%
- Travel & lodging$1181%
- Food & beverage$1571%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $3,668 |
| Sanofi | 1 | $3,607 |
| Sanofi US Services Inc. | 1 | $3,294 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,000 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Strensiq$2,313
How this compares
$12,587 in reported general payments places this provider in the 50th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 55 | $84,926 |
| XifaxanRifaximin | 20 | $61,410 |
| Tacrolimus | 225 | $28,775 |
| PrografTacrolimus | 18 | $18,811 |
| CellceptMycophenolate Mofetil | 13 | $13,855 |
| Sirolimus | 16 | $11,949 |
| Mycophenolate Mofetil | 68 | $9,131 |
| EliquisApixaban | 16 | $8,988 |
| Ursodiol | 74 | $7,803 |
| Mycophenolic AcidMycophenolate Sodium | 14 | $4,059 |
| Nadolol | 16 | $880 |
| Pantoprazole Sodium | 72 | $787 |
| Entecavir | 27 | $601 |
| Tamsulosin Hcl | 48 | $546 |
| Amlodipine Besylate | 41 | $305 |
Paid to pharmacies, not to this prescriber.
Other hepatology in New York
- Robert BrownNew York$967K
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Meena BansalNew York$208K
- Tatyana KushnerNew York$181K
- Howard WormanNew York$119K
- Augusto Villanueva RodriguezNew York$33K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.